legacy

Central and Latin American (CELAC) and European (EU) consortium for a personalized medicine approach to Gastric Cancer (LEGACy)

Tania Fleitas Kanonnikoff

Oncóloga Médica e investigadora

Hospital Clínico Universitario Valencia

INCLIVA | VLC
Instituto de Investigación Sanitaria

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No GA825832

DISCLOSURES

- Employment: None; Stock Ownership: None
- Consultant or Advisory Role: None
- Research Funding: Daiichi Sankyo, Beigine
- Speaking: Amgen

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No GA825832

CONSORCIO

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No GA825832

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

legacy



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Data source: GHO
Map production: CSU
World Health Organization

World Health Organization

© WHO 2016. All rights reserved

CA: A Cancer Journal for Clinicians, Volume: 68, Issue: 6, Pages: 394-424, First published: 12 September 2018, DOI: (10.3322/caac.21492)

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No GA825832

Estimated age-standardized incidence and mortality rates (World) in 2018, worldwide, both sexes, all ages



Data source: Globocan 2018
Graph production: Global Cancer Observatory (http://gco.iarc.fr)

International Agency for Research on Cancer
World Health Organization

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries



CA: A Cancer Journal for Clinicians, Volume: 68, Issue: 6, Pages: 394-424, First published: 12 September 2018, DOI: (10.3322/caac.21492)

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No GA825832

EL CRIBADO PUEDE MEJORAR LA SUPERVIVENCIA A LARGO PLAZO: LA EXPERIENCIA JAPONESA





Five years survival rates (%) of gastric cancer in various countries.

Asaka M and and Mabe K.
Proc Jpn Acad Ser B Phys Biol Sci. 2014 Jul 31; 90(7): 251–258.

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No GA825832

EL POTENCIAL DE LA ERRADICACIÓN DE *H.PYLORI* EN JAPÓN



Tsuda M. et al Helicobacter. 2017 Oct; 22(5): e12415.

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No GA825832

EL CANCER GÁSTRICO EN PAÍSES EUROPEOS Y LATINOAMERICANOS



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No GA825832

TCGA Study (~3-4 Major GC Genomic Subtypes)



A) Chromosomal Instability (CIN)

B) Microsatellite Instability (MSI

C) Genome Stable (GS)

D) Epstein-Barr Virus (EBV)

USA TCGA (2014) *Nature*

EL DESAFÍO DE ABORDAR LA HETEROGENEIDAD TUMORAL DEL CÁNCER GÁSTRICO



Fig. 2. Spatial ITH of HER2 expression in GC. Both images represent well-differentiated tubular adenocarcinoma, with variable HER2 immunoreactivity between the tumour clones, from strong and complete membranous staining to weak and incomplete membranous staining. HER2 IHC, low magnification (**a**), ×100 magnification (**inset**), and ×200 magnification (**b**).

Gullo I, Carneiro F et al. Pathobiology. 2018;85(1-2):50-63.

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No GA825832

legacy

OBJETIVO: Mejorar los resultados de GC mediante la aplicación de medicina personalizada en los tres niveles de prevención en las poblaciones de la UE y CELAC en base a una estrategia de modelo conceptual de "epidemiología integrativa ómica".



Modified from Sebastian Kaulitzki, www.shutterstock.com

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No GA825832

OBJETIVOS: INTERVENCIÓN INTEGRAL CONTRA EL CÁNCER GÁSTRICO



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No GA825832

LEGACY

WP1. Consensus algorithm for patient stratification(INCLIVA)

WP2. Epidemiological studies (INCAN)

WP3. Complex Data Analysis (VHIO)

Clinical studies

- CS1. GC risk factors
- CS2. GC multi-omic characterization
- CS3. Interventional study

WP4. Translation to clinical practice (IAF)

WP4.1 Educational mentoring programme (ULEI)

WP5. Communication and Dissemination (ECPC)

WP7. Ethical requirements

WP6. Coordination and management - INCLIVA

This project has received funding from the European Union's Horizon 2020 research and innovation pro

Legacy 1: Factores de riesgo de cáncer gástrico asociados con las poblaciones de la UE y CELAC.

Colección de Datos epidemiológicos



n= 800 casos y controles

Colección de Datos clínicos

Diseño del estudio: estudio de casos y controles
Objetivos primarios
a) Identificar los factores de riesgo asociados con GC en las poblaciones de la CELAC y la UE.
b) Identificar diferencias clínicas, demográficas y epidemiológicas.

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No GA825832

Status del reclutamiento Legacy 1



Center	INCLIVA	INCAN	PUC	VHIO	IPATIMUP	GENPAT	IAF	VUMC
Cases	21	0	15	0	14	9	0	0
Controls	4	0	26	0	3	1	0	0



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No GA825832

Legacy 2:
Caracterización multiómica del Cáncer Gástrico



Algoritmo diangóstico



N=400 casos
y controles

Training cohort: EU

Validation cohort: EU-CELAC

Primeros resultados septiembre 2020

Diseño del estudio: estudio de cohorte observacional.
Objetivos primarios
- Caracterización multimómica
-Diferencias regionales en las poblaciones de la UE y CELAC.
-Biomarcadores útiles para el algoritmo de diagnóstico.
-GC registro hospitalario

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No GA825832

Status del reclutamiento Legacy 2



Center	INCLIVA	INCAN	PUC	VHIO	IPATIMUP	GENPAT	IAF	VUMC
Cases	10	0	15	0	14	7	0	0
Control	2	0	26	0	3	1	0	0



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No GA825832

Legacy 3: estudio de intervención

1-3 meses luego…..

N= 800 sujetos



Objetivos primarios
-Para determinar el conocimiento sobre los factores de riesgo y síntomas de GC.
-Analizar el impacto de nuestro programa de intervención educativa.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No GA825832

Legacy 3: Registro del *H. pylori* y terapias



N= 800 casos

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No GA825832

Status del reclutamiento Legacy 3

Center	INCLIVA	INCAN	PUC	VHIO	IPATIMUP	GENPAT	IAF	VUMC
H. pylori registry	9	0	0	0	0	0	0	0
Educational intervention	7	100	0	0	0	0	0	0



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No GA825832

This proje

WP4. On-line course: Programme update

	Date	Topic	Speaker[#]
1	Apr 10th 2019	Personalized treatment of GC – current status	ULEI
2	Jul 11th 2019	IHC profiling of GC (protocol update) Update from AACR / ASCO / IGCC / ESMO-GI	IPATIMUP ULEI
3	Oct 8th 2019	Molecular Epidemiology of the EBV Gastric Cancer Subtype Immune microenvironment on GEA Update from ESMO	INCLIVA VUMC INCLIVA
4	Jan 30th 2020	Microbiome profiling of GC (protocol update) GC microbiome – an overview NCI summer cancer prevention course experience	IPATIMUP INCLIVA INCLIVA
5	May 15th 2020	FACE TO FACE COURSE IN PORTO	IPATIMUP
7	8 Oct 2020	Update Clinical Study 3 Complex data analysis	IAF ANAX
8	7 Jan 2021	IHC results sharing Initial Results WP1	GENPAT INCLIVA

* It was proposed that the GAM (associated to the face-to-face course) will be held at PORTO in May 15th-16th, so the course could be May 14th. In this case, we could flip these sessions (5 and 6).

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No GA825832

Legacy researchers at the Kick-off meeting, January 2019

Legacy educational event at Aras de Los Olmos, November 2019

Legacy researchers INCLIVA TEAM, September 2019

MORE INFO AT
https://legacy-h2020.eu/

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No GA825832

legacy

Muchas Gracias

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No GA825832